Drug Profile
Research programme: myocardial perfusion imaging agents - Lantheus Medical Imaging
Alternative Names: [18F]-RP1012Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb Medical Imaging
- Developer Lantheus Medical Imaging
- Class Imaging agents; Pyridazines; Radiopharmaceutical diagnostics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Myocardial ischaemia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Myocardial-ischaemia(Diagnosis) in USA
- 13 Aug 2008 Preclinical development is ongoing in USA
- 27 Sep 2007 Data presented at the European Society of Cardiology Congress 2007 (ESC-2007) added to the Diagnostic Agents pharmacodynamics section